Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.

Br J Cancer · 2017 · PMC5589984 · PMID 28772281

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other numeric differences in PFS, which did not reach statistical significance, were observed for patients aged ⩾65 years in whom PFS was shorter for the linsitinib/erlotinib treatment arm compared with the placebo/erlotinib arm (127 days vs 171 days; HR=1.30, 95% CI, 0.72–2.34).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.